Hexarelin Acetate, also named Examorelin, EP-23905 or MF6003, belongs to the first-generation synthetic hexapeptide growth hormone secretagogue (GHS) family. It is a structural analog of GHRP-6, distinguished by the unique D-2-methyl-tryptophan modification at position 2 of the peptide chain. This methylation design significantly improves protease resistance and enhances receptor binding affinity, making Hexarelin one of the most potent ghrelin receptor agonists among classic GHRP peptides. The product is provided as acetate salt, which optimizes aqueous solubility, reduces aggregation during lyophilization and reconstitution, and stabilizes the peptide backbone for long-term preservation. C-terminal amidation further protects the molecule from exopeptidase cleavage in biological experimental systems.

Hexarelin features a dual-receptor mechanism that differentiates it sharply from GHRP-2, GHRP-6 and other similar secretagogues. Its primary target is GHS-R1a, the ghrelin receptor expressed on pituitary somatotrophs and hypothalamic neurons. Upon receptor binding, it activates Gq-PLC-IP3-Ca2? intracellular signaling cascades to trigger strong pulsatile growth hormone release. Its GH stimulation potency surpasses many other GHRP peptides, and it can still induce obvious GH secretion even under high endogenous somatostatin background in laboratory models. When combined with GHRH analogues such as CJC-1295, it produces synergistic GH releasing effects, which is widely adopted in endocrinology research exploring hormone axis interaction. The secondary biological activity comes from binding to CD36 scavenger receptors on cardiomyocytes, vascular endothelial cells and macrophages. This CD36-mediated effect delivers cardioprotective properties independent of GH secretion, making Hexarelin an exclusive research tool for cardiovascular laboratory investigation.

Preclinical studies demonstrate that Hexarelin can mitigate myocardial ischemia-reperfusion injury, inhibit cardiomyocyte apoptosis, reduce oxidative stress and alleviate cardiac fibrosis. Apart from cardiac research, this peptide is widely applied across multiple research branches, including neuroendocrine regulation, somatotroph cell function, IGF-1 downstream signaling, metabolic balance and inflammatory response modulation. It should be noted that continuous administration may lead to GHS-R1a receptor desensitization, and high experimental doses can trigger mild elevation of cortisol and prolactin, which are key reference factors for researchers designing in vitro and in vivo experimental protocols.

Our Hexarelin Acetate is synthesized by solid-phase peptide synthesis technology. Each amino acid residue is sequentially coupled, followed by cleavage, global deprotection and salt transformation to obtain acetate salt crude peptide. Multiple rounds of preparative reversed-phase HPLC purification are implemented to remove truncated fragments, deletion sequences, unreacted raw materials, residual protecting groups and oxidation by-products generated on tryptophan residues. Every batch undergoes comprehensive quality control workflows, including HPLC purity detection, ESI mass spectrometry molecular identity confirmation, amino acid composition analysis, moisture testing and visual appearance inspection. Complete COA, HPLC chromatogram and mass spectrum documents can be provided for each shipment to satisfy strict laboratory audit and record-keeping requirements. Lyophilization is adopted to lock molecular conformation and slow oxidative degradation during international shipment and long-term frozen preservation. This product is supplied to university laboratories, biotech R&D institutes and pharmaceutical preclinical research teams for pituitary endocrinology experiments, ghrelin receptor pharmacology, myocardial injury models, growth hormone pathway exploration and peptide ligand screening projects.